Dennis A. Hesselink
Department of Internal Medicine
Division of Nephrology and Renal Transplantation
Erasmus MC
Rotterdam
Netherlands
Name/email consistency: high
- The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity. Hesselink, D.A., Bouamar, R., van Gelder, T. Ther. Drug. Monit (2010)
- Procalcitonin as a biomarker for severe Plasmodium falciparum disease: a critical appraisal of a semi-quantitative point-of-care test in a cohort of travellers with imported malaria. Hesselink, D.A., Burgerhart, J.S., Bosmans-Timmerarends, H., Petit, P., van Genderen, P.J. Malar. J. (2009)
- CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Hesselink, D.A., van Schaik, R.H., van Agteren, M., de Fijter, J.W., Hartmann, A., Zeier, M., Budde, K., Kuypers, D.R., Pisarski, P., Le Meur, Y., Mamelok, R.D., van Gelder, T. Pharmacogenet. Genomics (2008)
- A drug transporter for all ages? ABCB1 and the developmental pharmacogenetics of cyclosporine. Hesselink, D.A., van Schaik, R.H., Nauta, J., van Gelder, T. Pharmacogenomics (2008)
- The effects of renal transplantation on circulating dendritic cells. Hesselink, D.A., Vaessen, L.M., Hop, W.C., Schoordijk, W., Ijzermans, J.N., Baan, C.C., Weimar, W. Clin. Exp. Immunol. (2005)
- Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Hesselink, D.A., van Hest, R.M., Mathot, R.A., Bonthuis, F., Weimar, W., de Bruin, R.W., van Gelder, T. Am. J. Transplant. (2005)
- The effects of chronic kidney disease and renal replacement therapy on circulating dendritic cells. Hesselink, D.A., Betjes, M.G., Verkade, M.A., Athanassopoulos, P., Baan, C.C., Weimar, W. Nephrol. Dial. Transplant. (2005)
- The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression?. Hesselink, D.A., van Gelder, T., van Schaik, R.H. Pharmacogenomics (2005)
- Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid. Hesselink, D.A., van Gelder, T. Clin. Pharmacol. Ther. (2005)
- The use of cyclosporine in renal transplantation. Hesselink, D.A., Smak Gregoor, P.J., Weimar, W. Transplant. Proc. (2004)
- Experience with cyclosporine in endogenous uveitis posterior. Hesselink, D.A., Baarsma, G.S., Kuijpers, R.W., van Hagen, P.M. Transplant. Proc. (2004)
- The relative importance of cyclosporine exposure in heart, kidney or liver transplant recipients on maintenance therapy. Hesselink, D.A., van Dam, T., Metselaar, H.J., Balk, A.H., Mathôt, R.A., Smak Gregoor, P.J., Weimar, W., van Gelder, T. Transpl. Int. (2004)
- Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Hesselink, D.A., van Gelder, T., van Schaik, R.H., Balk, A.H., van der Heiden, I.P., van Dam, T., van der Werf, M., Weimar, W., Mathot, R.A. Clin. Pharmacol. Ther. (2004)
- Profiles of the acute-phase reactants C-reactive protein and ferritin related to the disease course of patients with systemic lupus erythematosus. Hesselink, D.A., Aarden, L.A., Swaak, A.J. Scand. J. Rheumatol. (2003)
- Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. Hesselink, D.A., Ngyuen, H., Wabbijn, M., Gregoor, P.J., Steyerberg, E.W., van Riemsdijk, I.C., Weimar, W., van Gelder, T. Br. J. Clin. Pharmacol (2003)
- Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Hesselink, D.A., van Schaik, R.H., van der Heiden, I.P., van der Werf, M., Gregoor, P.J., Lindemans, J., Weimar, W., van Gelder, T. Clin. Pharmacol. Ther. (2003)
